These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 19088876)

  • 1. A role for non-antimicrobial actions of tetracyclines in combating oxidative stress in periodontal and metabolic diseases: a literature review.
    Soory M
    Open Dent J; 2008; 2():5-12. PubMed ID: 19088876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-antimicrobial properties of tetracyclines--dental and medical implications.
    Rawal SY; Rawal YB
    West Indian Med J; 2001 Jun; 50(2):105-8. PubMed ID: 11677904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Chemically Modified Tetracyclines in the Management of Periodontal Diseases: A Review.
    Ghangurde AA; Ganji KK; Bhongade ML; Sehdev B
    Drug Res (Stuttg); 2017 May; 67(5):258-265. PubMed ID: 28268238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities.
    Tilakaratne A; Soory M
    Open Dent J; 2014; 8():109-24. PubMed ID: 24976875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host modulation with tetracyclines and their chemically modified analogues.
    Golub LM; Suomalainen K; Sorsa T
    Curr Opin Dent; 1992 Mar; 2():80-90. PubMed ID: 1325849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical use of tetracyclines in the treatment of periodontal diseases].
    Bokor-Bratić M; Brkanić T
    Med Pregl; 2000; 53(5-6):266-71. PubMed ID: 11089368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical applications of non-antimicrobial tetracyclines in dermatology.
    Monk E; Shalita A; Siegel DM
    Pharmacol Res; 2011 Feb; 63(2):130-45. PubMed ID: 20937386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation.
    Gu Y; Lee HM; Sorsa T; Salminen A; Ryan ME; Slepian MJ; Golub LM
    Pharmacol Res; 2011 Dec; 64(6):573-9. PubMed ID: 21771657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial and non-antimicrobial tetracyclines in human cancer trials.
    Richards C; Pantanowitz L; Dezube BJ
    Pharmacol Res; 2011 Feb; 63(2):151-6. PubMed ID: 20951804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity.
    Golub LM; McNamara TF; D'Angelo G; Greenwald RA; Ramamurthy NS
    J Dent Res; 1987 Aug; 66(8):1310-4. PubMed ID: 3040832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetracycline inhibition and the cellular source of collagenase in gingival crevicular fluid in different periodontal diseases. A review article.
    Ingman T; Sorsa T; Suomalainen K; Halinen S; Lindy O; Lauhio A; Saari H; Konttinen YT; Golub LM
    J Periodontol; 1993 Feb; 64(2):82-8. PubMed ID: 8433257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nonantimicrobial properties of tetracycline for the treatment of periodontal disease.
    Vernillo AT; Ramamurthy NS; Golub LM; Rifkin BR
    Curr Opin Periodontol; 1994; ():111-8. PubMed ID: 8032451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking Periodontal Disease Progression by Inhibiting Tissue-Destructive Enzymes: A Potential Therapeutic Role for Tetracyclines and Their Chemically-Modified Analogs.
    Rifkin BR; Vernillo AT; Golub LM
    J Periodontol; 1993 Aug; 64 Suppl 8S():819-827. PubMed ID: 29539753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs.
    Golub LM; Ramamurthy NS; McNamara TF; Greenwald RA; Rifkin BR
    Crit Rev Oral Biol Med; 1991; 2(3):297-321. PubMed ID: 1654139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes.
    Uitto VJ; Firth JD; Nip L; Golub LM
    Ann N Y Acad Sci; 1994 Sep; 732():140-51. PubMed ID: 7978787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs.
    Rifkin BR; Vernillo AT; Golub LM
    J Periodontol; 1993 Aug; 64(8 Suppl):819-27. PubMed ID: 8410621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxycycline and other tetracyclines in the treatment of bone metastasis.
    Saikali Z; Singh G
    Anticancer Drugs; 2003 Nov; 14(10):773-8. PubMed ID: 14597870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors.
    Holmes SG; Still K; Buttle DJ; Bishop NJ; Grabowski PS
    Bone; 2004 Aug; 35(2):471-8. PubMed ID: 15268899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature.
    Griffin MO; Fricovsky E; Ceballos G; Villarreal F
    Am J Physiol Cell Physiol; 2010 Sep; 299(3):C539-48. PubMed ID: 20592239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The non-antibiotic properties of tetracyclines: clinical potential in ophthalmic disease.
    Federici TJ
    Pharmacol Res; 2011 Dec; 64(6):614-23. PubMed ID: 21843641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.